

Li

SH

Wa

Wi



**PAN MERSEY AREA PRESCRIBING COMMITTEE**  
**PRESCRIBING POLICY STATEMENT**  
REF: G221 FINAL  
APC BOARD DATE: 27 JUN 2018  
**PENDING CCG APPROVAL**



**Pan Mersey**  
Area Prescribing Committee

## **GUSELKUMAB solution for injection (Tremfya® ▼) for Plaque Psoriasis**

**RED**

**The Pan Mersey Area Prescribing Committee recommends the prescribing of GUSELKUMAB solution for injection (Tremfya® ▼) in specialist settings only, for treating plaque psoriasis in accordance with NICE TA521.**

NICE technology appraisal (TA) 521<sup>1</sup> recommends guselkumab as an option for treating plaque psoriasis in adults, only if:

- > the disease is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10, and
- > the disease has not responded to other systemic therapies, including ciclosporin, methotrexate and PUVA (psoralen and long-wave ultraviolet A radiation), or these options are contraindicated or not tolerated, and
- > the company provides the drug according to the commercial arrangement.

Guselkumab treatment should be discontinued at 16 weeks if the psoriasis has not responded adequately. An adequate response is defined as:

- > a 75% reduction in the PASI score (PASI 75) from when treatment started **or**
- > a 50% reduction in the PASI score (PASI 50) and a 5-point reduction in DLQI from when treatment started.

Prescribing and monitoring of therapy must be retained by a specialist in the management of plaque psoriasis.

NICE does not expect this guidance to have a significant impact on resources; that is, it will be less than £5 million per year in England (or £9,100 per 100,000 population). This is because the technology is an option alongside current standard treatment options and is available at a similar price.

This guidance is not intended to affect the position of patients whose treatment with guselkumab was started within the NHS before this guidance was published. Treatment of those patients may continue without change to whatever funding arrangements were in place for them before this guidance was published until they and their NHS clinician consider it appropriate to stop.

### **Reference**

1. National Institute for Health and Care Excellence. Technology Appraisal guidance (TA) 521: Guselkumab for treating moderate to severe plaque psoriasis, 13<sup>th</sup> June 2018. Accessed 13.6.18 at: <https://www.nice.org.uk/guidance/ta521/resources/guselkumab-for-treating-moderate-to-severe-plaque-psoriasis-pdf-82606835435461>

**Note:** Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.